Poland· PL-100492206
Takhzyro
A lanadelumab product containing lanadelumabum, registered in Poland by Takeda Pharmaceuticals International AG. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lanadelumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Lanadelumab · ATC B06AC05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanadelumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lanadelumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$857.11
The record
At a glance
URPL (Poland)- Active substance
- Lanadelumabum
- Manufacturer
- Takeda Pharmaceuticals International AG
- Country
- Poland (PL)
- ATC code
- B06AC05
- ATC class
- Lanadelumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07038319163270
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lanadelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomTakhzyro 150mg/1ml solution for injection pre-filled syringesTakeda UK Ltd
- CzechiaTAKHZYROTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- SpainTAKHZYRO 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATakeda Pharmaceuticals International Ag Ireland Branch
- IcelandTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- NorwayTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- BelgiumTakhzyro 150 mgTakeda Pharmaceuticals International Ireland Branch
- SwedenTAKHZYRO 150 mg Injektionsvätska, lösning i förfylld sprutaTakeda Pharmaceuticals International AG Ireland Branch
- SwitzerlandTAKHZYRO 150 mg, Injektionslösung in einer FertigspritzeTakeda Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Takhzyro
- Liechtenstein · Takhzyro
- Norway · Takhzyro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2016bff-8a0b-4564-bed6-158dcbe1b990 GET /v1/drugs/d2016bff-8a0b-4564-bed6-158dcbe1b990?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "150 mg",
"packaging": "07038319163270 ¦ Rpz ¦ EU/1/18/1340/007 ¦ 152836\n1 amp.-strzyk. \nRpz ¦ EU/1/18/1340/008 ¦ 152837\n2 amp.-strzyk. \nRpz ¦ EU/1/18/1340/009 ¦ 152838\n6 amp.-strzyk.",
"substance": "Lanadelumabum 150 mg",
"common_name": "Lanadelumabum",
"pl_product_id": "100492206",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lanadelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.